Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00229385

Enrollment

Registered

2005-09-29

Start date

2006-01-31

Completion date

2010-04-30

Last updated

2013-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder, Schizophrenia

Brief summary

Comparing schizophrenic patients with comorbid OCD and schizophrenic patients without OCD in response to Ziprasidone and in cognitive functioning as compared with OCD patients

Interventions

DRUGZiprasidone

40-80 mg BID

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of Schizophrenia and OCD for at least 6 months * Minimum score of 14 on YBOCS * Minimum score of 60 on PANSS * Diagnosis of Schizophrenia without OC symptoms

Exclusion criteria

* Patients who are already being treated with ziprasidone * Diagnosis of schizophreniform disorder * Organic brain syndrome, mental retardation and pervasive developmental disorder * Patients having any significantly cardiovascular illness or electrolyte imbalance

Design outcomes

Primary

Measure	Time frame
YBOCS	8 weeks

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026